tients treated so far with QbG10 in the different
studies, we can see the following
picture: QbG10 seems to be active as a monotherapy; however,
combination with an allergen extract
at a standard dose appears to enhance the therapeutic effect. The
highest efficacy was achieved
when QbG10 was combined with a dose of allergen extract usually
applied in conventional
desensitization therapy, i.e. a 10-times higher dose than the one
tested in this present study. In a
next clinical trial we will test higher doses of CYT003-QbG10
monotherapy and compare the safety
and efficacy profile directly with the most promising product
formulations of CYT005-AllQbG10 in
order to select the best product candidate for late stage
development.”
CYT003-QbG10 Conference Call and Webcast
Cytos Biotechnology will host a conference call and Q&A session
today, Tuesday, May 15, 2007 at
10 am (CET) to discuss the study findings.
To access the conference call, please dial the following
numbers:
Europe +41 91 610 56 00
U.S. +1 866 291 41 66
U.K. +44 207 107 06 11
The conference call will be held in English and will also be
accessible by webcast on the internet.
You may follow the call live or have it replayed later on demand.
To access the webcast and the
presentation, please follow the link provided on our homepage
www.cytos.com.
The presentation
slides will be available for download 30 minutes prior to the
conference call.
Among other projects, Cytos Biotechnology will also discuss its
allergy program at the company’s
upcoming R&D day on Wednesday, June 20, 2007 at 2 pm (CET) at
the company’s premises in
Schlieren.
About the phase IIa study and the analysis
The multi-centre, randomized, double-blind and placebo-controlled
phase IIa study included 40 male
'"/>Page: 1 2 3 4 5 6 7 Related medicine technology :1.
Neose Announces Presentation of Positive Preclinical Data on
GlycoPEGylated Factor VIIa at the XXI Congress of the International
Society on Thrombosis and Haemostasis2.
Positive Aggrastat Results Featured in the Journal of the American
College of Cardiology3.
Portola Pharmaceuticals Announces Positive Data from a Phase II
Study of its Factor Xa Inhibitor at the XXI Congress of the
International Society on Thrombosis and Haemostasis4.
Protox Announces Positive Clinical Data from Prostate Cancer Study5.
AM-Pharma Announces Positive Results of Phase IIa Clinical Trial
with Alkaline Phosphatase For Ulcerative Colitis6.
Cougar Biotechnology Announces Presentation of Positive CB7630
Clinical Data at ESMO Conference7.
TransPharma Medical Announces Positive Results of Phase I Clinical
Trials for Transdermal Delivery of hPTH (1-34) for Osteoporosis
Treatment8.
Positive ZIO-201 Interim Phase II Sarcoma Data Presented at
European Society for Medical Oncology9.
Cosmo Pharmaceuticals Reports Positive Preliminary Phase II/III
Data with Rifamycin MMX in Infectious Diarrhea10.
Portola Pharmaceuticals Announces Positive Phase II EXPERT Results
and Additional Oral and Poster Presentations at the XXI Congress of
the International Society on Thrombosis and Haemostasis (ISTH)11.
Chi-Med Announces Positive Phase II Proof-of-Concept Data for
HMPL-004 in Ulcerative Colitis